Major depressive disorder affected roughly 21 million U.S. adults in a single year. Its clinical definition requires a specific constellation of symptoms, including appetite changes in over half of cases and sleep disturbances in up to 80%.
Key Takeaways
- APA practice guidelines note DSM-5 requires at least 5 of 9 symptoms for MDD diagnosis, including depressed mood or anhedonia persisting for 2 weeks
- NIMH describes core MDD symptoms: depressed mood most of day nearly every day, markedly diminished interest/pleasure in activities
- Significant weight loss/gain or appetite change is present in 50-70% of MDD cases per meta-analysis
- According to the National Institute of Mental Health (NIMH), the 12-month prevalence of major depressive disorder (MDD) among U.S. adults aged 18 and older was 8.3% in 2019, equating to roughly 21 million adults
- The World Health Organization (WHO) reports that depression affects an estimated 280 million people worldwide as of 2023, with MDD being the most common form representing over 70% of cases
- In the Global Burden of Disease Study 2019, MDD contributed to 51.55 million incident cases globally in 2019, with a 49.9% increase from 1990
- Family history increases MDD risk 2-4 fold, per twin studies heritability 37%
- Childhood maltreatment raises MDD odds by 2.8 (95% CI 2.4-3.4), meta-analysis 16 studies
- Female gender OR 1.95 for MDD lifetime risk, GWAS data
- 50% MDD remit within 6 months untreated, but 80% recur
- Suicide attempt risk 15-20% lifetime in MDD
- MDD disability-adjusted life years (DALYs) 50 million globally 2019
- SSRI antidepressants remit 50-60% first-line MDD per APA guidelines
- CBT achieves 40-50% response rate in MDD, meta-analysis 115 trials
- ECT remission 70-90% severe MDD, APA task force
Major depressive disorder affects about 8.3 percent of U.S. adults and can include symptoms lasting at least two weeks.
Related reading
01 · Category
Clinical Symptoms and Diagnosis25 stats
01
APA practice guidelines note DSM-5 requires at least 5 of 9 symptoms for MDD diagnosis, including depressed mood or anhedonia persisting for 2 weeks
02
NIMH describes core MDD symptoms: depressed mood most of day nearly every day, markedly diminished interest/pleasure in activities
03
Significant weight loss/gain or appetite change is present in 50-70% of MDD cases per meta-analysis
04
Insomnia or hypersomnia occurs in 75-80% of patients with MDD, according to APA review
05
Psychomotor agitation or retardation observed in 46% of MDD inpatients, per systematic review
06
Feelings of worthlessness or excessive guilt in 60-70% of MDD episodes, NIMH data
07
Diminished ability to think/concentrate or indecisiveness in 65% MDD cases
08
Recurrent thoughts of death or suicidal ideation in 50% of untreated MDD, per STAR*D study
09
PHQ-9 score >=10 has 88% sensitivity, 88% specificity for MDD diagnosis
10
Hamilton Depression Rating Scale (HAM-D) mean score in moderate MDD is 17-23
11
Anhedonia correlates with 85% of MDD cases per fMRI studies
12
Melancholic subtype features diurnal mood variation in 30% MDD, worse mornings
13
Atypical MDD shows hypersomnia in 76%, hyperphagia in 78%
14
Cognitive impairment in executive function persists in 40% remitted MDD
15
Somatic symptoms like fatigue present in 80-90% MDD patients
16
MADRS scale sensitivity for MDD diagnosis is 71% at cutoff 19
17
DSM-5 specifier for anxious distress in MDD occurs in 50-60%
18
Psychotic features in severe MDD in 15-20% cases
19
Seasonal pattern specifier in 10% MDD, more in women
20
Beck Depression Inventory (BDI-II) cutoff 14-19 indicates moderate MDD with 91% accuracy
21
Mixed features specifier (DSM-5) hypomania symptoms in 28% MDD
22
Pain symptoms comorbid in 65% MDD per WHO survey
23
Sleep EEG shows reduced REM latency <65 min in 80% endogenous MDD
24
Composite International Diagnostic Interview (CIDI) diagnoses MDD with 92.7% reliability
25
MINI International Neuropsychiatric Interview sensitivity 94.8% for MDD
Interpretation
Clinical Symptoms and Diagnosis Interpretation
The clinical portrait of Major Depressive Disorder is not a single sorrow but a stringent, multifaceted siege, where a hollowed mood and a deadened joy must first breach the gates, soon joined by a grim parliament of symptoms—from a body out of rhythm and a mind in chains to a soul besieged by guilt—all conspiring to prove that this is not merely sadness, but a systemic takeover of the self.
02 · Category
Epidemiology and Prevalence29 stats
01
According to the National Institute of Mental Health (NIMH), the 12-month prevalence of major depressive disorder (MDD) among U.S. adults aged 18 and older was 8.3% in 2019, equating to roughly 21 million adults
02
The World Health Organization (WHO) reports that depression affects an estimated 280 million people worldwide as of 2023, with MDD being the most common form representing over 70% of cases
03
In the Global Burden of Disease Study 2019, MDD contributed to 51.55 million incident cases globally in 2019, with a 49.9% increase from 1990
04
CDC data from the National Health Interview Survey (NHIS) 2021 shows that 13.9% of U.S. adults experienced symptoms of depression in the past 2 weeks, with MDD diagnosed in 8.4%
05
A meta-analysis in JAMA Psychiatry found the pooled lifetime prevalence of MDD in Europe to be 14.0% (95% CI, 12.9%-15.2%) across 27 studies
06
NIMH statistics indicate that women are 1.7 times more likely than men to have MDD, with 10.5% of women vs. 6.5% of men affected in the past year (2020 data)
07
In adolescents aged 12-17, the prevalence of MDD reached 17.1% in 2021 per NIMH, up from 8.4% in 2015
08
WHO estimates that in low- and middle-income countries, only 23% of people with depression receive formal health care, impacting MDD treatment rates globally
09
The Lancet Psychiatry study reported a global point prevalence of MDD at 4.4% (95% UI 4.1-4.7%) in 2020
10
U.S. adults aged 18-25 had the highest past-year MDD prevalence at 18.6% according to NSDUH 2021
11
In Australia, the lifetime prevalence of MDD is 17.1% per the National Survey of Mental Health and Wellbeing (2007)
12
European College of Neuropsychopharmacology data shows 30 million Europeans suffer from depression annually, with MDD predominant
13
In Japan, the point prevalence of MDD is 3.2% among adults per a 2020 national survey
14
Brazilian Longitudinal Study of Adult Health found 5.8% prevalence of MDD in a cohort of over 15,000 adults
15
In South Africa, the prevalence of lifetime MDD is 9.8% according to the South African Stress and Health Study
16
NIMH reports Black/African American adults have a past-year MDD prevalence of 7.4%, compared to 9.1% for White adults (2020)
17
During COVID-19, MDD prevalence in the U.S. increased to 27.8% from 8.5% pre-pandemic per HPS study
18
In China, a 2020 meta-analysis estimated MDD prevalence at 3.4% (95% CI 2.9-4.0%) post-COVID
19
Indian Journal of Psychiatry reports 5.3% current prevalence of MDD in community samples
20
Canadian Community Health Survey (2012) found lifetime MDD at 11.3% for adults
21
In the UK, NHS data shows 3.8% of adults screened positive for depression in 2019, with MDD at 2.5%
22
Global prevalence of MDD in children under 13 is 1.7% per meta-analysis
23
In elderly U.S. adults (65+), MDD prevalence is 2.7% past year (NIMH 2020)
24
Mexico's National Survey of Epidemiological Depression (ENDEP) found 4.5% MDD prevalence
25
Russia reports 5.5% annual MDD incidence per national registry (2018)
26
In Germany, the GEDA study 2014 showed 7.1% lifetime MDD in women, 4.4% in men
27
New Zealand Health Survey 2019/20: 5.9% current depression, MDD subset 4.1%
28
In France, OBéDI survey estimated 8.8% MDD prevalence in general population
29
Italy's national survey (2015) reports 3.0% 12-month MDD prevalence
Interpretation
Epidemiology and Prevalence Interpretation
These statistics paint a world that is, quite literally, sick with sadness, proving that depression is not a personal failing but a global epidemic that demands our collective attention.
03 · Category
Etiology and Risk Factors25 stats
01
Family history increases MDD risk 2-4 fold, per twin studies heritability 37%
02
Childhood maltreatment raises MDD odds by 2.8 (95% CI 2.4-3.4), meta-analysis 16 studies
03
Female gender OR 1.95 for MDD lifetime risk, GWAS data
04
Obesity BMI>30 increases MDD risk HR 1.55 (1.22-1.98), prospective cohort
05
Smoking current OR 1.5 for MDD onset, Mendelian randomization
06
Low socioeconomic status OR 1.52 for MDD, UK Biobank 500k
07
Chronic medical illness like diabetes OR 1.8 MDD risk
08
Genetic variants in SLC6A4 (5-HTTLPR) interact with stress OR 2.1
09
Parental divorce before 18 increases MDD risk RR 1.7
10
Sleep disturbance prior to MDD onset in 40%, longitudinal study
11
Inflammation CRP>3mg/L OR 1.62 MDD incidence, meta-analysis
12
Urban living OR 1.39 MDD risk, 20 studies meta
13
Adverse childhood experiences score >=4 OR 3.2 MDD, ACE study
14
Hypothalamic-pituitary-adrenal axis hyperactivity cortisol OR 1.5
15
Cannabis use disorder OR 2.3 MDD comorbidity
16
Unemployment OR 2.0 MDD onset within 2 years, cohort
17
BDNF Val66Met polymorphism OR 1.4 MDD susceptibility
18
Intimate partner violence OR 2.9 MDD women, meta-analysis
19
Vitamin D deficiency <20ng/ml OR 1.31 MDD risk
20
Early life stress epigenetically alters FKBP5 gene, OR 2.5 MDD
21
Shift work disorder OR 1.8 MDD, meta-analysis 7 studies
22
Loneliness score high OR 1.7 MDD prospective
23
Lead exposure childhood OR 1.6 adult MDD
24
Perfectionism trait OR 1.9 MDD recurrence
25
Gut microbiota dysbiosis OR 1.4 MDD, fecal transplant trials
Interpretation
Etiology and Risk Factors Interpretation
Depression doesn't arrive by one road but by a convoy of genetic blueprints, life's early sucker punches, and the steady drip-drip of modern stressors, all conspiring to prove that your brain is an organ that can, unfortunately, catch a cold from almost anything.
More related reading
04 · Category
Prognosis and Societal Impact23 stats
01
50% MDD remit within 6 months untreated, but 80% recur
02
Suicide attempt risk 15-20% lifetime in MDD
03
MDD disability-adjusted life years (DALYs) 50 million globally 2019
04
Chronic MDD >2 years duration in 20-30% cases
05
Relapse rate 50% within 2 years after first remission
06
MDD increases all-cause mortality HR 1.6 (1.3-2.0), meta-analysis
07
Work productivity loss $44 billion annually U.S. MDD
08
30% MDD develop bipolar disorder lifetime
09
Remission rates drop to 15% after 3 failed treatments, STAR*D
10
MDD shortens life expectancy 7-11 years, cohort studies
11
Comorbid anxiety doubles MDD chronicity odds
12
Early onset MDD <25 years 4x recurrence risk
13
Global economic cost MDD $1 trillion/year lost productivity, WHO
14
Suicide accounts 800,000 deaths/year, 50% MDD-related
15
Functional impairment persists 30% remitted MDD
16
MDD increases dementia risk HR 1.65 elderly
17
Absenteeism 28 days/year MDD vs 11 general pop
18
Postpartum MDD 15% incidence, 50% chronic >6 months
19
Treatment-resistant MDD 30% cases, poorer prognosis
20
Childhood MDD 50% adult persistence risk
21
Cardiovascular disease risk HR 1.3 MDD, meta 20 studies
22
Divorce rate 2x higher MDD patients
23
MDD healthcare costs $100 billion U.S. annually
Interpretation
Prognosis and Societal Impact Interpretation
While its tyranny can briefly wane for half its captives without a fight, major depression is a wickedly recurrent and systemic assassin, hijacking decades of life, unraveling minds and societies alike, and leaving a trail of broken hearts, bankrupt coffers, and graves accounting for nearly half the world’s suicides.
05 · Category
Treatment and Interventions25 stats
01
SSRI antidepressants remit 50-60% first-line MDD per APA guidelines
02
CBT achieves 40-50% response rate in MDD, meta-analysis 115 trials
03
ECT remission 70-90% severe MDD, APA task force
04
TMS FDA-approved, 50% response rate MDD nonresponders
05
SNRIs like venlafaxine 55% remission vs 40% SSRI, STAR*D level 2
06
Mindfulness-based cognitive therapy reduces MDD relapse 43%
07
Bupropion smoking cessation aids MDD with 60% efficacy
08
Ketamine IV 0.5mg/kg 70% response 24h MDD
09
Psilocybin-assisted therapy 71% response 1-week MDD
10
Exercise 150min/week moderate OR 0.62 MDD symptoms, meta 49 RCTs
11
Omega-3 1g/day adjunct 50% better remission MDD
12
Interpersonal psychotherapy (IPT) 50% remission acute MDD
13
Lithium augmentation 50% response SSRI nonresponders
14
VNS FDA-approved chronic MDD 27% response long-term
15
SAMe 1600mg/day adjunct 43% response MDD, meta-analysis
16
Light therapy 10,000 lux 60min SAD-MDD 67% response
17
Aripiprazole augmentation 25% added remission STAR*D
18
Behavioral activation therapy 48% remission MDD
19
Esketamine nasal 70% response TRD 4 weeks, SUSTAIN-2
20
DBT adapted MDD 59% remission vs TAU
21
Folic acid 0.5mg + SSRI 40% faster remission MDD
22
rTMS 10Hz left DLPFC 55% response MDD, meta 81 RCTs
23
Vortioxetine 10-20mg 52% remission MDD, REVIVE trial
24
ACT therapy reduces MDD symptoms SMD -0.68, meta-analysis
25
DBS subcallosal cingulate 90% long-term response severe MDD
Interpretation
Treatment and Interventions Interpretation
The sobering truth of depression treatment is that while we have a diverse arsenal of moderately effective tools—from pills and therapy to magnets and light—the most powerful interventions often carry the highest burden, leaving us to navigate a landscape where the best path is a stubbornly personal puzzle of trade-offs between efficacy, risk, and access.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Major Depressive Disorder Statistics. Gitnux. https://gitnux.org/major-depressive-disorder-statistics
MLA
James Okoro. "Major Depressive Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/major-depressive-disorder-statistics.
Chicago
James Okoro. 2026. "Major Depressive Disorder Statistics." Gitnux. https://gitnux.org/major-depressive-disorder-statistics.
Sources & references
16 datasets cited across this report · attribution is report-level